Optimal Oncologic Management and mTOR Inhibitor Introduction Are Safe and Improve Survival in Kidney and Liver Allograft Recipients With De Novo Carcinoma

International Journal of Cancer - United States
doi 10.1002/ijc.31769
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Antitumor Effect of Sorafenib and mTOR Inhibitor in Liver Transplantation Recipients With Hepatocellular Carcinoma Recurrence

Liver Transplantation
HepatologyTransplantationSurgery
2018English

Outcomes of De Novo Allograft Diabetic Nephropathy in Renal Allograft Recipients

Experimental and Clinical Transplantation
Transplantation
2013English

Renal Allograft Survival in Transplant Recipients With Focal Segmental Glomerulosclerosis

Journal of Nephropathology
Nephrology
2019English

mTOR Direct Crosstalk With STAT5 Promotes De Novo Lipid Synthesis and Induces Hepatocellular Carcinoma

Cell Death and Disease
Molecular NeuroscienceImmunologyCell BiologyCancer ResearchCellularMedicine
2019English

Extended Pharmacologic Thromboprophylaxis in Oncologic Liver Surgery Is Safe and Effective

Journal of Thrombosis and Haemostasis
MedicineHematology
2017English

Impact of Preformed and De Novo Anti-Hla DP Antibodies in Renal Allograft Survival

Transplant Immunology
TransplantationImmunologyAllergy
2016English

Letter: The Effect of Sirolimus on Recurrence and Survival in Liver Transplant Recipients With Hepatocellular Carcinoma-Authors’ Reply

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2018English

Focal Segmental Glomerulosclerosis (FSGS) Recurrence in Kidney Allograft Recipients

2011English

Practical Recommendations for Long-Term Management of Modifiable Risks in Kidney and Liver Transplant Recipients

Transplantation
Transplantation
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy